A Trial Among HealthCare Workers (HCW) Vaccinated With Janssen Vaccine: the SWITCH Trial (SWITCH)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT04927936|
Recruitment Status : Recruiting
First Posted : June 16, 2021
Last Update Posted : June 30, 2021
|First Submitted Date ICMJE||June 6, 2021|
|First Posted Date ICMJE||June 16, 2021|
|Last Update Posted Date||June 30, 2021|
|Actual Study Start Date ICMJE||June 25, 2021|
|Estimated Primary Completion Date||September 2022 (Final data collection date for primary outcome measure)|
|Current Primary Outcome Measures ICMJE
||Determination of antibodies by a quantitative IgG assay (LIAISON SARS-CoV-2 TrimericS IgG essay) 28 days after booster [ Time Frame: 28 days after booster ]
LIAISON® SARS-CoV-2 TrimericS IgG assay
|Original Primary Outcome Measures ICMJE||Same as current|
|Current Secondary Outcome Measures ICMJE||Not Provided|
|Original Secondary Outcome Measures ICMJE||Not Provided|
|Current Other Pre-specified Outcome Measures||Not Provided|
|Original Other Pre-specified Outcome Measures||Not Provided|
|Brief Title ICMJE||A Trial Among HealthCare Workers (HCW) Vaccinated With Janssen Vaccine: the SWITCH Trial|
|Official Title ICMJE||A Multicenter, Randomised, Single-blind, Controlled Trial Among HealthCare Workers (HCW) Vaccinated With Janssen Vaccine: the SWITCH Trial|
The key objective of the study is to measure the immune response against SARS-CoV-2 after different vaccinations in Health Care Workers (HCW) from 18 to 65 years old vaccinated once with Janssen vaccine.
Determination of antibodies by a quantitative immunoglobulin G (IgG) assay (LIAISON SARS-CoV-2 TRIMERICS IgG essay) 28 days after second vaccination (booster) comparing, per protocol, the following three groups:
Rationale: A novel coronavirus (SARS CoV-2) was first detected in Wuhan, China in December 2019 (1). In January 2021 the first vaccines protecting against this virus are available in the Netherlands. Most current available vaccines in the Netherlands (e.g., AstraZeneca vaccine (2), Moderna vaccine (3), and Pfizer vaccine (4) require a second boost (2nd vaccination) after the prime (1st vaccination), to obtain an optimal immune response. The booster (2nd vaccination) has up to present always been given with the same vaccine as the primary vaccine. Unfortunately, the availability of the vaccines is limited and a speedy vaccination is also hampered by logistic reasons. The ability to combine different vaccines could make vaccination programs in the future more flexible. It would facilitate a fast-track process and reduce the impact of any supply-chain disruptions (5). In addition, several studies in mice have already shown that combining different vaccines (two-dose heterologous vaccination regimen) can elicit a broader immune response (in field of neutralizing antibodies and T-cell responses)(6, 7). These results endorse the need for clinical trials to investigate the immunogenicity of heterologous regimens. Trails to combine different vaccines have meanwhile been set up in Great Britain and Spain where they combine Pfizer vaccine and AstraZeneca vaccine (Com-COV 1(8) and CombiVacS(9)). Recently, it became known that the CoM-COV1 was expanded with Moderna vaccine and Novavax vaccine (CoM-COV2(10)). Therefore this protocol has a focus to adeno priming with Janssen vaccine, which is not studied in the other ongoing studies. As the vaccination rate in The Netherlands is increasing rapidly, it was decided to include Healthcare Workers (HCW) vaccinated once with Janssen vaccine. Objective: The key objective of the study is to measure the immune response against SARS-CoV-2 after different vaccinations in Health Care Workers (HCW) from 18 to 65 years old.
Determination of antibodies by a quantitative IgG assay (LIAISON SARS-CoV-2 TrimericS IgG essay) 28 days after second vaccination (booster) comparing, per protocol, the following three groups:
Setting: multicenter study conducted at 4 academic University Medical Centers (UMC) hospitals (Amsterdam UMC, Erasmus UMC, Leiden UMC, and UMC Groningen).
Hypothesis: Immunogenicity in participants who have already received one dose of Janssen vaccine will be higher when it is followed by a heterologous booster containing Pfizer vaccine or Moderna vaccine as opposed to a homologous booster containing Janssen vaccine.
The main question that will be addressed: Measuring the humoral immune response against SARS-CoV-2 after inoculation with a single-dose Janssen vaccine compared to a homologous vaccination regimen with Janssen vaccine/Janssen vaccine and the comparison of a homologous vaccination regimen (Janssen vaccine/Janssen vaccine) with a heterologous vaccination regimen (Janssen vaccine/Pfizer vaccine + Janssen vaccine/Moderna vaccine).
Participants will be randomized for Standard of Care (1 vaccination with Janssen vaccine), a homologue vaccination strategy (two vaccines from the same manufacturer, i.e., Janssen vaccine) or a heterologous vaccination strategy (two different vaccines, e.g., Janssen vaccine followed by Pfizer vaccine or Moderna vaccine). The study starts approximately 84 days (+/- 10) after the first vaccination Janssen vaccine. The day of the 2nd vaccination is seen as day 0. Blood will be drawn at 4 different time points, i.e. day 0 - baseline (before 2nd vaccination), day 28 (after 2nd vaccination - primary endpoint), day 180 +/- 14 days (after 2nd vaccination), and day 365 +/- 14 days (after 2nd vaccination). Questionnaires will be used to monitor for adverse reactions after 2nd vaccination and to evaluate COVID-19 infection during the study and outcome despite vaccination.
Study population: Healthcare Workers (HCW) from 18 to 65 years old vaccinated once with Janssen vaccine. Individuals of all ethnicities will be recruited. Given the speed of the Dutch vaccination campaign, it is not feasible to collect baseline immunological data before first vaccination. For this reason, the baseline in this study is at the day of the booster (2nd vaccination). If not enough HCW can be found within the recruiting hospitals, the population will be expanded to HCW in surrounding peripheral hospitals and primary care (e.g., local pharmacies, dental practices, and physiotherapists).
Intervention (if applicable): All adult people in the Dutch population are vaccinated on a voluntary basis. The only difference is that they might be vaccinated with a different vaccine for the boost (second vaccination).
Main study parameters/endpoints:
Primary endpoint: to determine whether the immune response 28 days after boost is higher to that observed following only one vaccination (Janssen vaccine solo vs. Janssen vaccine/Janssen vaccine) and the comparison of a heterologous boost of a COVID-19 vaccine (84 days post prime (1st vaccination) - Janssen vaccine/Pfizer vaccine and Janssen vaccine/Moderna vaccine) with a homologous boost (84 days post prime (1st vaccination) - Janssen vaccine/Janssen vaccine), in participants vaccinated once with Janssen vaccine.
Secondary endpoints: to assess safety & reactogenicity of different prime-boost schedules of COVID-19 vaccines and characterization of immunogenicity of different prime-boost schedules of COVID-19 vaccines.
Nature and extent of the burden and risks associated with participation, benefit and group relatedness: The consequence of participating in this study has two sides; on the one hand, a higher burden for the participant, given 4 study visits in one year including blood samples and questionnaires. With the fact that slightly more side effects may be seen in the first 48 hours after the second vaccination (11). In contrast, in a prospective study from Germany with the same vaccination strategy, they identified a comparable reactogenicity between heterologous (Astra Zeneca vaccine/Pfizer vaccine) and homologous (Pfizer vaccine/Pfizer vaccine) booster vaccination after a 12-week dose interval (12). On the other hand, participants receive an overview of their own immune response after vaccination at several time points and their participation contributes to answering a very relevant research question. The burden of the study visits is expected to be minimal.
|Study Type ICMJE||Interventional|
|Study Phase ICMJE||Not Applicable|
|Study Design ICMJE||Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description:
Masking: Single (Participant)
A multicenter, randomised, single-blind, controlled trial to determine reactogenicity and immunogenicity of different prime-boost COVID-19 vaccine schedules.
Setting Multicenter study conducted through 4 academic trial sites (Amsterdam UMC, Erasmus MC, Leiden UMC, and UMC Groningen).
Trial duration Total duration of each participant will be 12 months from the administration of the boost vaccine dose.
Primary Purpose: Prevention
Participants will be randomised per cohort in 1:1:1:1 fashion using block randomisation.
The study will be single-blind. Staff involved in study will be aware of which vaccine the participant is receiving (arm allocation); the participants will remain blinded to their vaccine allocation.
Seven days (after filling in the questionnaires regarding side-effects) after the boost (2nd vaccination) the vaccination strategy will be unblinded. Directly after the boost (2nd vaccination) a letter will be given in which the study is explained and a statement is given that a second vaccination is given.
Those participants receiving only one shot with Janssen will only be told on the day of planned boost (2nd vaccination). They will not be vaccinated with placebo.
|Study Arms ICMJE||
|Publications *||Not Provided|
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
|Recruitment Status ICMJE||Recruiting|
|Estimated Enrollment ICMJE
|Original Estimated Enrollment ICMJE||Same as current|
|Estimated Study Completion Date ICMJE||September 2022|
|Estimated Primary Completion Date||September 2022 (Final data collection date for primary outcome measure)|
|Eligibility Criteria ICMJE||
|Ages ICMJE||18 Years to 65 Years (Adult, Older Adult)|
|Accepts Healthy Volunteers ICMJE||Yes|
|Listed Location Countries ICMJE||Netherlands|
|Removed Location Countries|
|NCT Number ICMJE||NCT04927936|
|Other Study ID Numbers ICMJE||MEC-2021-0132
2021-000701-24 ( EudraCT Number )
|Has Data Monitoring Committee||No|
|U.S. FDA-regulated Product||
|IPD Sharing Statement ICMJE||
|Responsible Party||Hugo van der Kuy, Erasmus Medical Center|
|Study Sponsor ICMJE||Erasmus Medical Center|
|PRS Account||Erasmus Medical Center|
|Verification Date||June 2021|
ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP